We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 1% below its sector, cheaper than its peers on earnings.
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save FAGR.BR and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
